A U Sabitov, D A Lioznov, K V Zhdanov, E P Tikhonova, E V Esaulenko, O P Kovtun, P L Kuznetsov, P V Sorokin
{"title":"[里亚米洛韦治疗 COVID-19 的疗效和安全性随机双盲多中心临床试验结果]。","authors":"A U Sabitov, D A Lioznov, K V Zhdanov, E P Tikhonova, E V Esaulenko, O P Kovtun, P L Kuznetsov, P V Sorokin","doi":"10.26442/00403660.2024.05.202770","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults.</p><p><strong>Materials and methods: </strong>The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial.</p><p><strong>Results: </strong>The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established.</p><p><strong>Conclusion: </strong>As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19].\",\"authors\":\"A U Sabitov, D A Lioznov, K V Zhdanov, E P Tikhonova, E V Esaulenko, O P Kovtun, P L Kuznetsov, P V Sorokin\",\"doi\":\"10.26442/00403660.2024.05.202770\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults.</p><p><strong>Materials and methods: </strong>The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial.</p><p><strong>Results: </strong>The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established.</p><p><strong>Conclusion: </strong>As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.</p>\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.26442/00403660.2024.05.202770\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2024.05.202770","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19].
Aim: To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults.
Materials and methods: The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial.
Results: The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established.
Conclusion: As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
